Introduction
============

Ovarian endometrioid carcinomas account for only 10% of all ovarian carcinomas ([@b1-ol-0-0-8626]). The majority of ovarian endometrioid carcinomas are thought to be type I, low-grade tumors with good prognosis ([@b1-ol-0-0-8626]). The precursor lesions of ovarian endometrioid carcinomas have been described as endometrioid borderline tumors (EBTs); however, EBTs are extremely rare and constitute only 0.2% of all epithelial ovarian tumors. EBTs exhibit two major growth patterns: Adenofibromatous and intracystic ([@b1-ol-0-0-8626]). The adenofibromatous type arises from benign ovarian adenofibroma, whereas the intracystic types arise from the transformation of endometriosis, as revealed by their frequent coexistence in surgical specimens ([@b2-ol-0-0-8626]). The process underlying the molecular pathogenesis of EBT remains unclear, whereas a number of molecular alterations have been described in ovarian endometrioid carcinomas, including mutations in β-catenin (16--38%) ([@b3-ol-0-0-8626]--[@b7-ol-0-0-8626]), phosphatase and tensin homolog (*PTEN*; 14--21%) ([@b8-ol-0-0-8626],[@b9-ol-0-0-8626]), AT-rich interaction domain 1A (*ARID1A*; 30%) ([@b10-ol-0-0-8626]), phosphoinositide-3-kinase catalytic α polypeptide (*PIK3CA*; 0%) ([@b11-ol-0-0-8626]) and tumor protein p53 (*TP53*; 60%) ([@b6-ol-0-0-8626],[@b12-ol-0-0-8626]).

Mutations in the tumor-suppressor gene *PTEN* have been reported in a relatively high percentage of endometrial and ovarian cancer cases, particularly in the endometrioid subtype ([@b9-ol-0-0-8626],[@b13-ol-0-0-8626],[@b14-ol-0-0-8626]). The majority of these mutations were observed in stage I tumors, indicating that *PTEN* inactivation represents an early event during ovarian tumorigenesis ([@b9-ol-0-0-8626]). However, *PTEN* mutations in EBTs have not previously been described, possibly due to their rarity. *PTEN*, located at chromosome 10q23, is a tumor-suppressor gene encoding a lipid phosphatase that dephosphorylates phosphatidylinositol 3,4,5-trisphosphate \[PI(3,4,5)P3\], performing opposing actions to phosphoinositide 3-kinase (PI3K) ([@b15-ol-0-0-8626],[@b16-ol-0-0-8626]). PI(3,4,5)P3 is converted to PI(3,4)P2, which activates the proto-oncogene protein kinase B (PKB; also known as AKT). When phosphorylated, AKT becomes activated and antagonizes apoptotic pathways via the activation of mechanistic target of rapamycin or the inactivation of the members of the forkhead family, whereas the dephosphorylation of PI(3,4,5)P3 by PTEN induces the activation of the apoptotic pathway ([@b17-ol-0-0-8626]--[@b19-ol-0-0-8626]). Therefore, the fundamental role of *PTEN* is the inhibition of the PI3K/AKT signaling pathway. *PTEN* mutations may disrupt this inhibitory role, thereby inducing the antiapoptotic pathway.

BAF250a, the protein encoded by *ARID1A* ([@b20-ol-0-0-8626],[@b21-ol-0-0-8626]), is one of the accessory subunits of the SWItch/Sucrose Non-Fermentable complex (SWI/SNF). SWI/SNF is a chromatin-remodeling complex that is found in all eukaryotes and is responsible for regulating gene expression during numerous cellular processes, including differentiation, development, DNA repair, proliferation, and tumor suppression ([@b22-ol-0-0-8626]). Using adenosine triphosphate, SWI/SNF mobilizes nucleosomes, thereby modulating the accessibility of promoters for transcriptional activation or repression. Rearrangement of *ARID1A* has been demonstrated in a breast cancer cell line, while a lung cancer cell line has been shown to exhibit *ARID1A* deletion, indicating that *ARID1A* is a tumor-suppressor gene ([@b22-ol-0-0-8626]). The nature and pattern of *ARID1A* mutations in ovarian endometrioid carcinoma also provide evidence of its role as a tumor suppressor ([@b10-ol-0-0-8626]). In a previous study, *ARID1A* mutations were revealed to frequently co-occur with *PIK3CA* gene mutations and PI3K/AKT signaling pathway activation, as demonstrated by the increased AKT1 activation in endometrial cancer ([@b23-ol-0-0-8626]). However, to the best of our knowledge, the roles of *ARID1A* mutation in EBTs have not previously been described. Therefore, the majority of these genetic alterations, which are prevalent in ovarian endometrioid carcinomas, induce the activation of the PI3K/AKT signaling pathway, and may serve major roles in carcinogenesis as well as disease progression.

The aim of the present study was to investigate the PI3K/AKT signaling pathway status in EBTs and the role of *PTEN* and *ARID1A* mutations. The present study examined the differences in *PTEN* and *ARID1A* mutations between benign and borderline patient tissue samples in order to gain insight into the molecular pathogenesis involved in the initiation of EBT.

Materials and methods
=====================

### Tissue samples

Formalin-fixed, paraffin-embedded (FFPE) tissue samples isolated from two cases of EBT of the ovaries were analyzed in the present study. Samples were obtained from the Department of Obstetrics and Gynecology at the Shimane University Hospital (Izumo, Japan) between March 2013 and December 2015. The patients were a 61-year-old female (case 1) and a 43-year-old female (case 2) who had presented with abdominal distension as the chief complaint. The patients had undergone laparoscopic bilateral salpingo-oophorectomy, and had no significant previous medical or family history of disease.

The resected specimens were sectioned (section thickness, 3 µm), stained with hematoxylin and eosin and reviewed by a pathologist. Subsequently, the tissue specimens were immunohistochemically stained with the following antibodies overnight at 4°C: Monoclonal anti-PTEN antibody (cat. no. ABM-2052; 1:100; Cascade BioScience, Inc., Winchester, MA, USA), anti-ARID1A (cat. no. sc-32761; 1:50; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-p53 (cat. no. 760-2542; 1:200; Roche Diagnostics, Indianapolis, IN, USA), anti-β-catenin (cat. no. ab32572; 1:1,000; Abcam, Cambridge, UK) and anti-phosphorylated (p)-AKT (cat. no. 4060; Ser473; 1:50; Cell Signaling Technology, Inc., Danvers, MA, USA) antibodies. The following day, slides were washed three times with PBS prior to the detection of antigens using the two-step DAKO EnVision+ Peroxidase System (DAKO; Agilent Technologies, Inc., Santa Clara, CA, USA), according to the manufacturer\'s protocol, at room temperature for 30 min. After rinsing with PBS, the sections were incubated at room temperature for 5 min in 0.05% diaminobenzidine in PBS with 0.03% H~2~O~2~.

Acquisition of tissue specimens was approved by the Ethics Committee of Shimane University School of Medicine (approval no. 2004-0381). Written informed consent was provided by all participants prior to enrollment in the present study. This study was conducted in accordance with the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001.

### Scoring of immunohistochemical staining

All samples were evaluated by two pathologists in Shimane University Hospital, who were blinded to the present study. The samples were scored negative for PTEN when complete loss of expression in the tumor sample was observed, with stromal cells and normal fallopian tube epithelial cells used as the positive controls. PTEN staining was considered positive when strong, weak or heterogeneous staining was observed.

Absence of nuclear staining of ARID1A is referred to as a 'clonal loss' pattern and corresponds to mutations in ARID1A ([@b10-ol-0-0-8626]); therefore, such tissues were scored as 'loss of expression'. Surrounding stromal cells and normal fallopian epithelial cells served as positive controls.

p53 was scored 'wild-type-like' when \<50% of the tumor cells demonstrated positive nuclear staining. p53 was scored 'mutant-like' if \>50% of the tumor cells exhibited strong positive nuclear staining or when discrete geographical patterns exhibited \>50% tumor cell positivity.

### DNA extraction

Borderline regions of both cases contained sufficient tumor tissue to extract DNA and perform sequence analysis. Benign epithelial regions were not observed in case 1. Tissue sections were placed on membrane slides and counterstained with hematoxylin for 1 min at room temperature. Selected tumor tissues were dissected, and after 48 h of digestion with Proteinase K solution (cat. no. 25530-049; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 56°C, DNA was extracted from the dissected samples using a QIAamp DNA Micro kit (Qiagen Inc., Valencia, CA, USA), according to the manufacturer\'s protocol.

### Sequence analysis

PCR amplification was performed for all 9 exons of *PTEN* using primers ([Table I](#tI-ol-0-0-8626){ref-type="table"}) and genomic DNA from dissected FFPE tissue. PCR amplification was performed in 20 µl reaction volumes that contained 75 mM Tris-HCl, 1.5 mM MgCl~2~, 50 mM KCl, 20 mM (NH4)~2~SO~4~, 0.2 mM of each primer, and 1 U *Taq* DNA polymerase (Takara Bio, Inc., Otsu, Japan). The PCR experiments were conducted under the following conditions: An initial 5 min denaturation at 95°C; 35 cycles of 1 min each at 94, 57, and 72°C; and a single final extension step for 10 min at 72°C. Amplified PCR products were sequenced at Beckman Coulter, Inc. (Brea, CA, USA) and analyzed using the Mutation Surveyor DNA Variant Analysis Software (version 4.0.6; SoftGenetics LLC, State College, PA, USA).

Results
=======

### Clinical findings

The tissue samples were obtained from a 61-year-old female (case 1) and a 43-year-old female (case 2) with abdominal distension as the chief complaint. The patients underwent laparoscopic bilateral salpingo-oophorectomy, and had no significant previous medical or family history of disease. The serum cancer antigen 125 expression levels were within normal limits (\<35.0 U/ml), and the results of the general examination were also normal. Following the initial surgical procedure, the patients underwent total hysterectomy and omentectomy due to the EBT diagnosis. Follow-up data was available in case 1 for 5 years and in case 2 for 2 years. The two patients were alive and well at the last follow-up.

Pathological findings
---------------------

### Case 1

Gross observations of the tumor of the right ovary revealed that it had a maximum diameter of 7.5 cm. Microscopically, the tumor was categorized as having an endometrioid adenofibromatous growth pattern. Numerous glands with intervening fibrous stroma were observed and these glands demonstrated varying degrees of endometrial hyperplasia, ranging from simple hyperplasia to a more marked proliferation, similar to that observed in complex atypical hyperplasia ([Fig. 1](#f1-ol-0-0-8626){ref-type="fig"}). No invasion of the ovarian stroma was identified.

### Case 2

Gross observations of the tumor in the left ovary revealed that its maximum diameter was 4.5 cm. Microscopically, the tumor was categorized as having an intracystic growth pattern. The tumor exhibited a papillary growth pattern protruding into a cystic space ([Fig. 2A](#f2-ol-0-0-8626){ref-type="fig"}). Cells with moderate cytological atypia were observed. Atypical endometrial glands were observed in the endometrial background ([Fig. 2B](#f2-ol-0-0-8626){ref-type="fig"}). No invasion of the ovarian stroma was identified.

### Immunohistochemical findings

Loss of PTEN protein expression was revealed in the nuclei of neoplastic cells in both EBTs. In case 2, loss of PTEN expression was identified not only in the area of endometriosis with atypia, but also endometriosis without atypia ([Fig. 3](#f3-ol-0-0-8626){ref-type="fig"}).

Loss of ARID1A protein expression was observed in the nuclei of neoplastic cells, whereas strong expression was maintained in stromal and normal fallopian tube epithelial cells of the same section in case 1 ([Fig. 4](#f4-ol-0-0-8626){ref-type="fig"}). In case 2, ARID1A expression was revealed to be present, and was most likely wild-type protein. Wild-type p53 and β-catenin expression patterns were observed in both tissue samples.

Furthermore, the expression level of p-AKT in these two cases was assessed. The tumor cells in case 1 were negative for p-Akt expression ([Fig. 5A](#f5-ol-0-0-8626){ref-type="fig"}); however, in case 2, p-AKT expression was not identified in the area of endometriosis without atypia, but was in the endometriosis with atypia ([Fig. 5B and C](#f5-ol-0-0-8626){ref-type="fig"}).

### PTEN mutational analysis

PCR amplification and sequence analysis were performed for the borderline regions in case 1 tissue samples, and in the benign and borderline regions in the case 2 tissue samples. The borderline regions of both samples were revealed to harbor a c.483insG mutation in exon 8 of the *PTEN* gene ([Fig. 6](#f6-ol-0-0-8626){ref-type="fig"}). Regarding the regions of endometriosis without atypia, the same mutations were detected. c.483insG represents a frameshift mutation that results in the formation of a stop codon (p.ASP485X) for *PTEN* protein translation.

Discussion
==========

There are few previous studies investigating EBTs due to their rarity; to the best of our knowledge, only two series and one case study have been previously reported ([@b24-ol-0-0-8626]--[@b26-ol-0-0-8626]). EBTs were observed in the right and left ovaries in 2--5% of cases at the time of diagnosis in these studies, and the predominant growth pattern was adenofibromatous in both case series, as well as in case 1 of the present study. Among all of these studies, only case 2 of the present study was demonstrated to be associated with endometriosis. Additionally, glandular and papillary proliferations with a high grade of complexity and mild atypia in the lining epithelial cells were identified in the present study. In all of the cases mentioned, no squamous differentiation was observed and there was no stromal invasion; the growth was limited to only one ovary with the capsule intact. In the long-term follow-up, both of the case series of EBTs demonstrated no signs of recurrence or metastasis, whereas 20% of patients with well-differentiated endometrioid carcinoma were revealed to have recurrence ([@b24-ol-0-0-8626]). It has been observed that the endometrioid neoplasms of the ovary are usually carcinomas, whereas borderline tumors are extremely rare, and are thought to arise from adenofibroma or endometriosis ([@b1-ol-0-0-8626]).

Ovarian endometrioid carcinomas are genetically stable and have been described to arise from EBT ([@b1-ol-0-0-8626]). They are associated with *PTEN, ARID1A, PIK3CA* and *TP53* mutations ([@b1-ol-0-0-8626]). *PTEN* mutations may represent an early event in the pathogenesis of endometrioidcarcinoma ([@b27-ol-0-0-8626]). However, the frequency of *PTEN* mutation in EBTs has not been described previously. These prevalent genetic alterations observed in ovarian endometrioid carcinoma are known to induce the activation of the PI3K/AKT signaling pathway ([@b6-ol-0-0-8626]). However, as EBTs are extremely rare, the status of genetic mutations in these tumors is yet to be reported.

The present study analyzed the status of genetic mutations in EBTs and their association with the activation of the PI3K/AKT signaling pathway for the first time. In case 1, which was associated with adenofibroma, *PTEN* and *ARID1A* mutations were observed. However, in case 2, which was associated with endometriosis, *ARID1A* mutation was not observed, whereas *PTEN* mutation was observed in EBT as well as in the area of endometriosis without atypia, although the PI3K/AKT signaling pathway was activated only in the EBT area. The results of genetic alteration analyses are provided in [Table II](#tII-ol-0-0-8626){ref-type="table"}. The observations suggest that the *PTEN* mutation represents an early event in EBT tumorigenesis, whereas the additional genetic alterations may be necessary in order for the PI3K/AKT signaling pathway to be activated and induce the development of EBT to invasive carcinoma. Additional studies will be required to confirm the findings and implications of the present study.
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![Case 1: Hematoxylin and eosin staining of endometrioid borderline tumor (adenofibromatous type). Mild cytological atypia is present in the endometrioid glands (magnification, ×400).](ol-16-01-0189-g00){#f1-ol-0-0-8626}

![Case 2: Hematoxylin and eosin staining of endometrioid borderline tumor (intracystic type). (A) Endometriosis with atypia demonstrated papillary growth pattern (magnification, ×400). (B) Endometriosis with/without atypia (magnification, ×200).](ol-16-01-0189-g01){#f2-ol-0-0-8626}

![Phosphatase and tensin homolog immunostaining. (A) Case 1, tumor (negative) (magnification, ×400). (B) Case 2, benign regions (negative) (magnification, ×800). (C) Case 2, borderline tumor (negative) (magnification, ×200). (D) Fallopian tube epithelial cells (positive control) (magnification, ×200).](ol-16-01-0189-g02){#f3-ol-0-0-8626}

![AT-rich interaction domain 1A immunostaining. (A) Case 1 tissue sample (negative) (magnification, ×200). (B) Fallopian tube epithelial cells (positive control) (magnification, ×200).](ol-16-01-0189-g03){#f4-ol-0-0-8626}

![Phosphorylated protein kinase B immunostaining. (A) Case 1 tissue sample (negative) (magnification, ×200). (B) Case 2 tissue sample including benign and borderline regions (benign regions: negative, borderline regions: positive) (magnification, ×200). (C) Borderline regions in case 2 tissue sample (positive) (magnification, ×400).](ol-16-01-0189-g04){#f5-ol-0-0-8626}

![DNA sequencing electropherograms showing the sequence of exon 8 of the phosphatase and tensin homolog gene sequenced from (A) case 1 and (B) case 2 tissue samples. The arrow indicates the insertion mutation at c.483insG.](ol-16-01-0189-g05){#f6-ol-0-0-8626}

###### 

Primers used for PCR amplification of the *PTEN* gene.

  Exon   Forward primer 5′-3′          Reverse primer 5′-3′
  ------ ----------------------------- ---------------------------
  1      TTCCATCCTGCAGAAGAAGC          CAGCCGCAGAAATGGATAC
  2      ACTCCAGCTATAGTGGGGAAA         TTTTCTGTGGCTTAGAAATCTTTT
  3      TGATTACTACTCTAAACCCATAGAAGG   TTGTTTTAGAAGATATTTGCAAGC
  4      AAAGATTCAGGCAATGTTTGTT        TCTCACTCGATAATCTGGATGAC
  5      TCCAGTGTTTCTTTTAAATACCTGTT    GATCCAGGAAGAGGAAAGGAA
  6      ATATATGTTCTTAAATGGCTACGA      ACATGGAAGGATGAGAATTTC
  7      TCATTAAAATCGTTTTTGACAGTTT     TCTGTCCTTATTTTGGATATTTCTC
  8      TGTTTAACATAGGTGACAGATTTTCTT   ACAAGTCAACAACCCCCACA
  9      TGTTCATCTGCAAAATGGAATAA       CACAATGTCCTATTGCCATTAAA

###### 

Genetic analyses of distinct tumor regions.

  Case no.   Tissue region                            PTEN     ARID1A   β-catenin   p53   p-AKT
  ---------- ---------------------------------------- -------- -------- ----------- ----- ----------
  Case 1     Borderline                               Mutant   Mutant   WT          WT    Negative
  Case 2     Benign (endometriosis without atypia)    Mutant   WT       WT          WT    Negative
             Borderline (endometriosis with atypia)   Mutant   WT       WT          WT    Positive

PTEN, phosphatase and tensin homolog; ARID1A, AT-rich interaction domain 1A; p-AKT, phosphorylated protein kinase B; WT, wild-type
